LWM
KIN

Liberty Wealth Management’s Kindred Biosciences, Inc. KIN Stock Holding History

Liberty Wealth Management’s Portfolio KIN Stock Details KIN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-250
Closed -$2K – 1015
2019
Q2 		$2K Buy
+250
New +$2.16K ﹤0.01% 787

Other funds holding KIN

PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Liberty Wealth Management's KIN Position: Q3 2019 in Review

Liberty Wealth Management sold out of Kindred Biosciences, Inc. (KIN) in Q3 2019, closing a stake of 250 shares — an estimated $2K sold.

Liberty Wealth Management first reported a position in KIN in Q2 2019 and held it in 1 quarter. The position peaked at $2K in Q2 2019. 72 funds tracked by Wall St. Rank hold KIN as of Q3 2019.

  • Liberty Wealth Management reported no remaining Kindred Biosciences, Inc. position as of Q3 2019 after selling out during the quarter.
  • Liberty Wealth Management sold 250 Kindred Biosciences, Inc. shares in Q3 2019, an estimated $2K.
  • Liberty Wealth Management first reported a position in Kindred Biosciences, Inc. in Q2 2019 and held it in 1 quarter.
  • Liberty Wealth Management's Kindred Biosciences, Inc. position peaked at $2K in Q2 2019.
  • 72 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q3 2019.

Based on Liberty Wealth Management's 13F filing for Q3 2019, filed 30 Oct 2019.